News | May 07, 2008

Contrast ECG Registry Explores Safety Concerns

May 7, 2008 – Lantheus Medical Imaging initiated CaRES (Contrast Echocardiography REgistry for Safety Surveillance), a multicenter Phase IV observational study that will further evaluate the safety profile of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension in patients with suboptimal echocardiograms, to explore the safety profile of DEFINITY for which the FDA posted an alert on Oct. 10, 2007.

In post-marketing use, four patients experienced fatal cardiac arrests either during or within 30 minutes of DEFINITY administration; one patient received DEFINITY and underwent a cardiac stress test, two patients had severe congestive heart failure and the fourth was undergoing mechanical ventilation for respiratory failure.

The open-label, nonrandomized registry will be conducted in at least 10 clinical sites in the U.S. and include at least 1,600 patients. The study will gather data on patient characteristics and demographics, indication for the contrast usage, safety monitoring of patients during and after DEFINITY administration and nature and frequency of any adverse events that may occur.

“The CaRES registry was established following discussions with the FDA to further explore the safety profile of DEFINITY as it is used in clinical practice. We believe this is the first large multi-center safety registry of its kind to be performed in the U.S.," said Mark Hibberd, M.D., Senior Medical Director, Lantheus Medical Imaging. "We expect the study to provide the physician community with important information about the safety profile of DEFINITY in patients with suboptimal non-contrast echo studies."

Activated DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The agent currently carries the “black box” warning from the FDA. The safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established.

For more information: http://www.fda.gov/CDER/drug/InfoSheets/HCP/microbubbleHCP.htm and http://www.nmh.org/nmh/heart/coronarydisease/main.htm

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init